sorangicin-a and Tuberculosis

sorangicin-a has been researched along with Tuberculosis* in 1 studies

Other Studies

1 other study(ies) available for sorangicin-a and Tuberculosis

Article	Year
The antibiotic sorangicin A inhibits promoter DNA unwinding in a Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-01, Volume: 117, Issue:48 Rifampicin (Rif) is a first-line therapeutic used to treat the infectious disease tuberculosis (TB), which is caused by the pathogen Topics: Aminoglycosides; Antibiotics, Antitubercular; Binding Sites; DNA-Directed RNA Polymerases; Drug Resistance, Bacterial; Humans; Models, Molecular; Molecular Conformation; Mycobacterium tuberculosis; Promoter Regions, Genetic; Protein Binding; Rifampin; Structure-Activity Relationship; Tuberculosis	2020

Article

Year

The antibiotic sorangicin A inhibits promoter DNA unwinding in a

Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-01, Volume: 117, Issue:48

Rifampicin (Rif) is a first-line therapeutic used to treat the infectious disease tuberculosis (TB), which is caused by the pathogen

Topics: Aminoglycosides; Antibiotics, Antitubercular; Binding Sites; DNA-Directed RNA Polymerases; Drug Resistance, Bacterial; Humans; Models, Molecular; Molecular Conformation; Mycobacterium tuberculosis; Promoter Regions, Genetic; Protein Binding; Rifampin; Structure-Activity Relationship; Tuberculosis

2020